- Previous Close
344.55 - Open
346.95 - Bid 340.05 x --
- Ask 342.35 x --
- Day's Range
340.10 - 355.20 - 52 Week Range
298.45 - 469.85 - Volume
67 - Avg. Volume
2,617 - Market Cap (intraday)
5.504B - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
33.33 - EPS (TTM)
10.27 - Earnings Date Feb 6, 2025 - Feb 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 20, 2019
- 1y Target Est
--
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, antifungals, corticosteroids, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, soft gelatin capsules, dry syrup, gripe water, and oral gel, powder, and liquid in the cardiovascular and anti-diabetics areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, and ROIVIT; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, creams, lotions, liquids, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
www.kilitch.com168
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: KILITCH.BO
View MorePerformance Overview: KILITCH.BO
Trailing total returns as of 1/21/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KILITCH.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KILITCH.BO
View MoreValuation Measures
Market Cap
5.54B
Enterprise Value
5.28B
Trailing P/E
33.52
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.52
Price/Book (mrq)
2.93
Enterprise Value/Revenue
3.37
Enterprise Value/EBITDA
18.66
Financial Highlights
Profitability and Income Statement
Profit Margin
8.32%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.51B
Net Income Avi to Common (ttm)
125.85M
Diluted EPS (ttm)
10.27
Balance Sheet and Cash Flow
Total Cash (mrq)
690.71M
Total Debt/Equity (mrq)
18.01%
Levered Free Cash Flow (ttm)
--